Bristol-Myers Squibb (New York) and Corgentech (South San Francisco, California), a privately held biotechnology company, have entered into an agreement to jointly develop and commercialize Corgentech’s E2F Decoy (edifoligide sodium), a first-of-its-kind E2F Decoy treatment currently in Phase III development for the prevention of vein graft failure following coronary artery bypass graft (CABG) and peripheral artery bypass graft surgery.